Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

STIL Block Versus Paravertebral Block for Pain Relief After Modified Radical Mastectomy (STIL-PVB-MRM)

16 novembre 2026 aggiornato da: Armia mohsen shafeek, National Cancer Institute, Egypt

Ultrasound-Guided Subtransverse Interligamentary (STIL) Block Versus Paravertebral Block (PVB) for Postoperative Analgesia in Modified Radical Mastectomy: A Randomized Controlled Trial

Breast cancer surgery, particularly modified radical mastectomy (MRM), can cause significant postoperative pain. Effective pain management is important to improve patient comfort, facilitate recovery, reduce opioid consumption, and potentially decrease the risk of persistent post-mastectomy pain.

This randomized controlled clinical trial aims to compare the effectiveness of ultrasound-guided subtransverse interligamentary (STIL) block and thoracic paravertebral block (PVB) for postoperative pain relief in female patients undergoing modified radical mastectomy.

Eligible patients will be randomly allocated into three groups: the STIL block group, the PVB group, and a control group receiving general anesthesia without a regional block. Both regional blocks will be performed under ultrasound guidance at the T4 thoracic level using 25 mL of 0.25% bupivacaine combined with 4 mg dexamethasone.

Postoperative pain will be assessed using a visual analogue scale (VAS) at rest and during movement. The study will also evaluate postoperative morphine consumption, time to first rescue analgesia, intraoperative fentanyl requirements, recovery characteristics, patient satisfaction, postoperative nausea and vomiting, and block-related complications.

The primary objective is to compare postoperative pain scores at rest 24 hours after surgery between patients receiving STIL block and those receiving PVB.

The findings may help determine whether STIL block provides an effective alternative to thoracic paravertebral block for postoperative analgesia following modified radical mastectomy.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

BACKGROUND AND RATIONALE:

Modified radical mastectomy (MRM) is a commonly performed surgical procedure for the management of breast cancer. Postoperative pain remains an important concern and may interfere with respiratory function, delay mobilization, prolong hospital stay, and negatively affect patient recovery and satisfaction.

Thoracic paravertebral block (PVB) is an established regional anesthesia technique for breast surgery that provides effective postoperative analgesia and reduces opioid requirements. However, it requires considerable technical expertise and carries potential complications, including pleural puncture, pneumothorax, vascular injury, and inadvertent neuraxial spread of local anesthetic.

The ultrasound-guided subtransverse interligamentary (STIL) block is a relatively novel paraspinal regional anesthesia technique. Local anesthetic is injected into the space between the transverse process and the intertransverse ligament, allowing spread toward the thoracic paravertebral space.

This study aims to compare the postoperative analgesic efficacy of STIL block with thoracic PVB in patients undergoing MRM.

STUDY DESIGN AND POPULATION:

This is a prospective, randomized, controlled clinical trial involving 60 female patients with breast cancer scheduled for modified radical mastectomy at the National Cancer Institute, Cairo University.

Eligible patients will be aged 18-65 years, have an ASA physical status of II-III, and a body mass index between 20 and 35 kg/m².

Patients will be randomly allocated into three equal groups, with 20 patients in each group:

Group I - STIL Block:

Patients will receive ultrasound-guided subtransverse interligamentary block at the T4 thoracic level before induction of general anesthesia.

Group II - Paravertebral Block:

Patients will receive ultrasound-guided thoracic paravertebral block at the T4 thoracic level before induction of general anesthesia.

Group III - Control:

Patients will receive general anesthesia without any regional nerve block.

INTERVENTION DETAILS:

Both regional anesthesia techniques will be performed approximately 30 minutes before induction of general anesthesia.

In the STIL group, a 22-gauge echogenic spinal needle will be advanced under ultrasound guidance into the subtransverse interligamentary space at T4. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.

In the PVB group, a 22-gauge echogenic spinal needle will be advanced under ultrasound guidance into the thoracic paravertebral space at T4. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.

All patients will receive standardized general anesthesia and multimodal postoperative analgesia according to the study protocol.

GENERAL ANESTHESIA AND POSTOPERATIVE ANALGESIA:

General anesthesia will be induced using intravenous propofol, fentanyl, and rocuronium and maintained with sevoflurane in oxygen-enriched air.

All patients will receive intravenous paracetamol 1 g and ketorolac 30 mg as part of the multimodal analgesic regimen, subject to suitability.

Postoperative analgesia will include intravenous paracetamol 1 g and ketorolac 30 mg every 8 hours. Rescue analgesia will be provided using intravenous morphine 3 mg increments whenever the visual analogue scale (VAS) pain score is ≥4.

OUTCOME ASSESSMENT:

Primary Outcome:

The primary outcome is the postoperative pain score at rest, assessed using the visual analogue scale (VAS) 24 hours after surgery, comparing the STIL and PVB groups.

Secondary Outcomes:

  1. Postoperative pain scores at rest and during movement at predefined time points.
  2. Total postoperative morphine consumption during the first 24 hours.
  3. Time to first rescue analgesic request.
  4. Total intraoperative fentanyl consumption.
  5. Hemodynamic parameters, including heart rate and mean arterial pressure.
  6. Dermatomal sensory distribution and block failure rate.
  7. Block performance time, number of needle passes, and number of attempts.
  8. Postoperative nausea and vomiting.
  9. Patient satisfaction with postoperative analgesia.
  10. Recovery characteristics.
  11. Block-related complications and adverse events.

BLINDING AND RANDOMIZATION:

Patients will be randomly allocated using a computer-generated randomization sequence and sequentially numbered opaque sealed envelopes.

The study will be double-blinded. Patients and postoperative outcome assessors will be unaware of group allocation. Regional blocks will be performed by an anesthesiologist who will not participate in postoperative data collection. Identical adhesive dressings will be applied to the thoracic area in all patients.

STATISTICAL ANALYSIS:

Data will be analyzed using IBM SPSS Statistics version 27. Appropriate parametric and nonparametric statistical tests will be used according to data distribution. A p-value ≤0.05 will be considered statistically significant.

Tipo di studio

Interventistico

Iscrizione (Stimato)

60

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Cairo, Egitto, 11796
        • Reclutamento
        • National Cancer Institute, Cairo University
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

**Inclusion Criteria:**

  1. Female patients scheduled for modified radical mastectomy for breast cancer.
  2. American Society of Anesthesiologists (ASA) physical status II-III.
  3. Age between 18 and 65 years.
  4. Body mass index (BMI) between 20 and 35 kg/m².

**Exclusion Criteria:**

  1. Patient refusal to participate.
  2. ASA physical status IV or higher.
  3. Age below 18 or above 65 years.
  4. BMI below 20 or above 35 kg/m².
  5. Known allergy to local anesthetics, opioids, or any of the study medications.
  6. History of chronic pain or psychiatric illness.
  7. Contraindications to regional anesthesia, including local infection at the injection site, coagulopathy, or pre-existing neuropathy.
  8. Severe cardiac, hepatic, renal, or respiratory disease.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: STIL Block Group

Patients will receive ultrasound-guided Subtransverse Interligamentary (STIL) block at the T4 thoracic level, performed approximately 30 minutes before induction of general anesthesia. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.

Ultrasound-guided Subtransverse Interligamentary (STIL) block performed at the T4 thoracic level approximately 30 minutes before induction of general anesthesia. A 22-gauge echogenic spinal needle will be advanced in-plane beneath the intertransverse ligament into the subtransverse interligamentary space. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.

Comparatore attivo: Paravertebral Block Group

Patients will receive ultrasound-guided thoracic Paravertebral Block (PVB) at the T4 thoracic level, performed approximately 30 minutes before induction of general anesthesia. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.

Ultrasound-guided thoracic paravertebral block performed at the T4 thoracic level approximately 30 minutes before induction of general anesthesia. A 22-gauge echogenic spinal needle will be advanced in-plane toward the thoracic paravertebral space. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.

Nessun intervento: Control Group

Patients will receive general anesthesia without any regional anesthesia block. Intraoperative and postoperative analgesia will be provided according to the standardized multimodal analgesic protocol, including intravenous paracetamol and ketorolac, with intravenous morphine as rescue analgesia when the VAS pain score is ≥4.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Postoperative Pain Score at Rest at 24 Hours
Lasso di tempo: 24 hours after surgery

Postoperative pain intensity at rest will be assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain), 24 hours after surgery. The primary comparison will be between the STIL block and paravertebral block groups.

24 hours after surgery

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Postoperative Pain Scores at Rest and During Movement
Lasso di tempo: PACU, 1, 2, 4, 6, 12, and 18 hours after surgery

Pain intensity will be assessed using the Visual Analogue Scale (VAS), ranging from 0 to 10, both at rest and during movement.

PACU, 1, 2, 4, 6, 12, and 18 hours after surgery

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Armia M shafeek, MD, National Cancer Institute, Cairo

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

10 novembre 2026

Completamento primario (Stimato)

1 novembre 2027

Completamento dello studio (Stimato)

1 dicembre 2027

Date di iscrizione allo studio

Primo inviato

16 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

16 novembre 2026

Primo Inserito (Effettivo)

20 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • AP2611-201-253-215

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be shared with other researchers because no data-sharing plan has been established for this study. Study results will be disseminated through scientific publications, while participant confidentiality and data privacy will be maintained in accordance with institutional ethical requirements.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .